デフォルト表紙
市場調査レポート
商品コード
1698006

サイケデリックドラッグ市場- 世界の産業規模、シェア、動向、機会＆予測、薬物タイプ別、用途別、流通チャネル別、地域別、競合別セグメント、2020-2030年

Psychedelic Drug Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Drug Type, By Application, By Distribution Channel, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 186 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.70円
代理店手数料はかかりません

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

サイケデリックドラッグ市場- 世界の産業規模、シェア、動向、機会＆予測、薬物タイプ別、用途別、流通チャネル別、地域別、競合別セグメント、2020-2030年
出版日: 2025年03月28日
発行: TechSci Research
ページ情報: 英文 186 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

サイケデリックドラッグの世界市場規模は2024年に45億5,000万米ドルとなり、予測期間では2030年までCAGR 10.55%で目覚ましい成長が予測されています。

世界のサイケデリックドラッグ市場は、臨床研究の著しい進歩、規制枠組みの進化、社会的認識の変化などに後押しされ、新たな関心の高まりと拡大が見られます。特にうつ病、不安障害、心的外傷後ストレス障害（PTSD）などの精神疾患の有病率が上昇しており、革新的で効果的な治療ソリューションに対する緊急の需要が生じています。サイケデリック・ベースの治療薬は、従来の抗うつ薬に代わる破壊的な選択肢として支持を集めており、臨床試験において迅速な発症と持続的な効能の両方を実証しています。

市場概要
予測期間 2026-2030
市場規模：2024年 45億5,000万米ドル
市場規模：2030年 83億2,000万米ドル
CAGR：2025年～2030年 10.55%
急成長セグメント 病院薬局
最大市場 北米

市場の成長は、メンタルヘルスに対する意識の高まり、進歩的な政策改革、サイケデリックの医学的有用性を裏付ける科学的証拠の増加によってさらに促進されています。製薬会社、バイオテクノロジー企業、研究機関の戦略的パートナーシップは医薬品開発のパイプラインを加速させ、精神科医療におけるサイケデリック化合物の主流への統合の可能性を位置づけています。規制当局の承認が拡大し、研究開発への投資が強化されるにつれて、サイケデリックドラッグ市場は長期的に大きく成長する態勢を整えています。

主な市場促進要因

精神疾患の有病率の上昇

主な市場課題

規制上のハードル

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のサイケデリックドラッグ市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬物の種類別（リゼルグ酸ジエチルアミド、ガンマヒドロキシ酪酸、ケタミン、シロシビン、その他）
    • 用途別（治療抵抗性うつ病、麻薬中毒、心的外傷後ストレス障害、ナルコレプシー、パニック障害、その他）
    • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
    • 地域別
    • 企業別（2024）
  • 製品市場マップ
    • 薬の種類別
    • 用途別
    • 流通チャネル別
    • 地域別

第6章 北米のサイケデリックドラッグ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のサイケデリックドラッグ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン

第8章 アジア太平洋地域のサイケデリックドラッグ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国

第9章 南米のサイケデリックドラッグ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのサイケデリックドラッグ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収
  • 製品上市

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Jazz Pharmaceuticals PLC
  • NeonMind Biosciences Inc.
  • Cybin Inc.
  • Pfizer Inc
  • Numinus Wellness Inc
  • Mind Medicine Inc
  • PharmaTher Holdings Ltd
  • NRX Pharmaceuticals Inc
  • Seelos Therapeutics Inc
  • Revive Therapeutics Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 17524

Global Psychedelic Drug Market was valued at USD 4.55 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 10.55% through 2030. The global psychedelic drug market is witnessing a renewed surge in interest and expansion, fueled by significant advancements in clinical research, evolving regulatory frameworks, and shifting societal perceptions. The rising prevalence of mental health disorders-particularly depression, anxiety, and post-traumatic stress disorder (PTSD)-has created an urgent demand for innovative and effective treatment solutions. Psychedelic-based therapeutics are gaining traction as a disruptive alternative to conventional antidepressants, demonstrating both rapid onset and sustained efficacy in clinical trials.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.55 Billion
Market Size 2030USD 8.32 Billion
CAGR 2025-203010.55%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Market growth is being further catalyzed by increasing mental health awareness, progressive policy reforms, and a growing body of scientific evidence supporting the medical utility of psychedelics. Strategic partnerships between pharmaceutical companies, biotech firms, and research institutions are accelerating drug development pipelines, positioning psychedelic compounds for potential mainstream integration within psychiatric care. As regulatory approvals expand and investment in research and development intensifies, the psychedelic drug market is poised for substantial long-term growth.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The increasing global prevalence of mental health disorders is one of the most significant catalysts driving the growth of the psychedelic drugs market. As traditional treatment approaches struggle to meet the rising demand for effective solutions, psychedelic-assisted therapies are emerging as a disruptive innovation in psychiatric care. The burden of mental health disorders has reached unprecedented levels, with conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD) affecting millions worldwide. According to data from the World Health Organization (WHO), depression affects more than 284 million individuals worldwide, making it one of the most widespread mental health conditions. Similarly, over 264 million people are impacted by anxiety disorders, highlighting the growing demand for effective mental health interventions. Despite these alarming statistics, conventional treatments-including selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT)-often produce suboptimal results, with many patients experiencing delayed symptom relief, treatment resistance, or severe side effects. This growing treatment gap has created a strong demand for innovative therapies, positioning psychedelics as a viable alternative.

Key Market Challenges

Regulatory Hurdles

Perhaps the most significant challenge facing the psychedelic drug market is the complex and evolving regulatory landscape. Many psychedelics are classified as controlled substances due to their historical association with recreational use and concerns about safety and abuse potential. Navigating these regulations can be a lengthy and expensive process, often requiring years of clinical trials and regulatory approvals.

Key Market Players

  • Jazz Pharmaceuticals PLC
  • NeonMind Biosciences Inc.
  • Cybin Inc.
  • Pfizer Inc
  • Numinus Wellness Inc
  • Mind Medicine Inc
  • PharmaTher Holdings Ltd
  • NRX Pharmaceuticals Inc
  • Seelos Therapeutics Inc
  • Revive Therapeutics Inc

Report Scope:

In this report, the Global Psychedelic Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychedelic Drug Market, By Drug Type:

  • Lysergic Acid Diethylamide
  • Gamma Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Others

Psychedelic Drug Market, By Application:

  • Treatment-Resistant Depression
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Narcolepsy
  • Panic Disorders
  • Others

Psychedelic Drug Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Psychedelic Drug Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychedelic Drug Market.

Available Customizations:

Global Psychedelic Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychedelic Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 5.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Drug Type
    • 5.3.2. By Application
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Psychedelic Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 6.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Psychedelic Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Psychedelic Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Psychedelic Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Psychedelic Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 7.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Psychedelic Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Psychedelic Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. France Psychedelic Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Psychedelic Drug Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Psychedelic Drug Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Psychedelic Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 8.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Psychedelic Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Japan Psychedelic Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. India Psychedelic Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Australia Psychedelic Drug Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. South Korea Psychedelic Drug Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. South America Psychedelic Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 9.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Psychedelic Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Psychedelic Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Psychedelic Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Psychedelic Drug Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 10.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Psychedelic Drug Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Psychedelic Drug Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Psychedelic Drug Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Jazz Pharmaceuticals PLC
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. NeonMind Biosciences Inc.
  • 14.3. Cybin Inc.
  • 14.4. Pfizer Inc
  • 14.5. Numinus Wellness Inc
  • 14.6. Mind Medicine Inc
  • 14.7. PharmaTher Holdings Ltd
  • 14.8. NRX Pharmaceuticals Inc
  • 14.9. Seelos Therapeutics Inc
  • 14.10. Revive Therapeutics Inc

15. Strategic Recommendations

16. About Us & Disclaimer